HEALTH

Aleksandra Rizo Appointed as CEO of Vividion Therapeutics

SAN DIEGO – January [24], 2023 – Vividion Therapeutics, Inc., (Vividion) a biopharmaceutical company utilizing recent discovery technologies to liberate high trace, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a unconditionally owned and independently operated subsidiary of Bayer AG, this day announced that current President and Head of Analysis and Pattern Aleksandra Rizo, M.D., Ph.D., will buy the role of President and Chief Govt Officer of Vividion and shall be a part of the Board of Directors. Jeffrey Hatfield, current Chief Govt Officer, will transition to the draw of Chairman of the Board of Directors at Vividion. Vividion will continue its mission to liberate high trace, traditionally undruggable target biology with precision therapeutics for cancers and immune disorders.

Beneath Jeffrey Hatfield’s leadership since 2020, Vividion has grown from a runt, compare startup to a mid-sized a hit biotech company with nearly about 200 workers. The company is already advancing a few recent biology, first-in-class applications in opposition to the health heart and has extra than a dozen identical pipeline alternatives rising in early discovery. In his recent role, Jeffrey Hatfield will continue to bewitch an active role within the growth and maturation of Vividion in opposition to a clinical-stage company, providing guidance and toughen on both company and R&D design.

“It’s an extremely thrilling time at Vividion, as we are beginning to advance a few applications from our chemoproteomics platform within the health heart and our compare pipeline and strategic partnerships continue to slump, said Jeffrey Hatfield. “I’m deeply grateful for the opportunity over the previous two years to handbook this world-class group at Vividion, and to accomplice with Bayer to possess our plump capacity. In my recent role as Board Chair, I live up for continuing to work with the Board and Aleksandra to reveal our precision therapeutics to the sufferers who desperately want them.”

“Jeff has been a key driver within the help of Vividion’s growth. We are very grateful for his visionary leadership and cosy that he will continue to work intently with us in his recent role as Chairman of the Board,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President of Bayer’s Pharmaceuticals Division. “With Aleksandra as the recent CEO, I am obvious Vividion will continue to thrive and advance in its mission to reveal transformative therapies to sufferers. We are all in favour of the long slump forward and live up for working with this extremely-revered chief.”

Since becoming a member of Vividion in 2022, Aleksandra Rizo has been the chief of the company’s Analysis and Pattern group, serving to to form the portfolio and advance the chemoproteomics platform. To relieve within the transition to Vividion’s subsequent share of growth, Aleksandra Rizo has intensive trade leadership ride building a runt biotech as effectively as a deep working out of work and thrive within a effectively-organized pharmaceutical ecosystem. An finished clinician and oncology knowledgeable with an right entrepreneurial spirit, Aleksandra Rizo has brought slightly a few applications from discovery, thru clinical construction to submission, a essential skill as the Vividion pipeline matures.

“We beget begun our shuffle to trade remedy and keep shut the boundaries of druggability for a fluctuate of ailments together with most cancers and immune disorders,” states Aleksandra Rizo. “Our applications are only about all concentrated on proteins the trade has previously seen as undruggable and existing the capacity to bring enormous trace to sufferers, if a hit. I live up for working with Jeff and the Board as we continue to excel in our discovery efforts and transition correct into a clinical-stage company. I’m able to no longer imagine a extra thrilling time to handbook Vividion.”

About Vividion
Vividion Therapeutics, Inc. a unconditionally owned and independently operated subsidiary of Bayer AG bought in August 2021, is a biopharmaceutical company utilizing recent discovery technologies to liberate high trace, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to name a entire bunch of previously unknown life like pockets on effectively-validated protein targets implicated in a extensive series of ailments, while concurrently figuring out compounds from its proprietary covalent chemistry library that interact in a extremely selective manner with these pockets. The company is leveraging its proprietary chemoproteomic platform to advance a varied pipeline of extremely selective runt molecule therapeutics concentrated on high trace, traditionally undruggable targets in oncology and immunology. For extra data, please consult with www.vividion.com.

About Bayer
Bayer is a global enterprise with core competencies within the lifestyles science fields of effectively being care and diet. Its companies and products are designed to help of us and the planet thrive by supporting efforts to grasp the key challenges offered by a rising and rising outdated worldwide population. Bayer is dedicated to driving sustainable construction and producing a teach impression with its corporations. At the identical time, the Personnel goals to elongate its earning energy and ranking trace thru innovation and growth. The Bayer mark stands for belief, reliability and quality all thru the enviornment. In fiscal 2021, the Personnel employed around 100,000 of us and had sales of 44.1 billion euros. R&D prices, forward of special objects, amounted to 5.3 billion euros. For extra data, scamper to www.bayer.com.

Gain extra data at https://pharma.bayer.com/
Snarl us on Facebook: http://www.facebook.com/bayer
Snarl us on Twitter: @BayerPharma

Contact:
Vividion Therapeutics
Patricia Allen
+1 (858)345-4690
[email protected]

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button